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Background: CST6 promoter is highly methylated in cancer, and its detection can provide important prognostic
information in breast cancer patients. The aim of our study was to develop a Methylation-Sensitive High Resolution
Melting Analysis (MS-HRMA) assay for the investigation of CST6 promoter methylation.
Methods: We designed primers that amplify both methylated and unmethylated CST6 sequences after sodium
bisulfate (SB) treatment and used spiked control samples of fully methylated to unmethylated SB converted
genomic DNA to optimize the assay. We first evaluated the assay by analyzing 36 samples (pilot training group)
and further analyzed 80 FFPES from operable breast cancer patients (independent group). MS-HRMA assay results
for all 116 samples were compared with Methylation-Specific PCR (MSP) and the results were comparable.
Results: The developed assay is highly specific and sensitive since it can detect the presence of 1% methylated
CST6 sequence and provides additionally a semi-quantitative estimation of CST6 promoter methylation. CST6
promoter was methylated in 39/80 (48.75%) of FFPEs with methylation levels being very different among samples.
MS-HRMA and MSP gave comparable results when all samples were analyzed by both assays.
Conclusions: The developed MS-HRMA assay for CST6 promoter methylation is closed tube, highly sensitive,
cost-effective, rapid and easy-to-perform. It gives comparable results to MSP in less time, while it offers the
advantage of additionally providing an estimation of the level of methylation.
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Methylation specific PCRBackground
DNA methylation is one of the most frequent epigenetic
events in the mammalian genome that usually occurs in
regions rich in CG dinucleotides. Alterations in DNA
methylation are very common in cancer cells; many tumor
suppressor genes which are normally unmethylated, when
they undergo aberrant DNA methylation are silenced and
as a consequence they are not expressed [1]. In particular,
hypermethylation has been reported as an early event in
breast cancer [2], frequently leading to gene silencing* Correspondence: lianidou@chem.uoa.gr
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distribution, and reproduction in any mediumthrough methylation of CpG-rich regions near the tran-
scriptional start sites of genes that regulate important cell
functions [3]. DNA methylation is believed to be an early
event in the process of cancer development and progres-
sion since tumor suppressor genes are frequently inacti-
vated at very early stages in human cancer. Thus, DNA
methylation is considered as a promising biomarker for
early detection and prognosis estimation in cancer
patients [4,5].
Sodium bisulfite (SB) modification of DNA is necessary
for DNA methylation assays that are based on PCR ampli-
fication, since DNA polymerase does not recognize methy-
lated nucleotides, and as a result methylation information
is lost during amplification. Through bisulfite treatmentd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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sines are transformed into uracils, while 5-methylcytosines
remain unaffected. There are two different approaches,
which allow DNA methylation analysis through PCR amp-
lification of SB modified DNA. The first approach is based
on design of primers that specifically amplify methylated
or unmethylated templates, and is adopted by methylation
specific PCR (MSP) and quantitative MSP. The second ap-
proach is based on primers that amplify a region of the
desired template including CpG islands, no matter what its
methylation status is. In this case, Methylation Independ-
ent PCR (MIP) is firstly performed and information on the
methylation status of that region is obtained through post-
PCR analyses techniques like bisulfite sequencing, restric-
tion digestion, single-strand conformation analysis, and
high-resolution melting [6].
High-Resolution Melting Analysis (HRMA) firstly intro-
duced in 2003 [7] has several advantages for clinical ana-
lysis, since it is a closed-tube, probe-free technique, rapid,
simple, cost-effective and non-destructive. Initially devel-
oped for mutation scanning and genotyping studies
[8-12], high-resolution melting technology can be useful
for the detection of methylation as well. Recently, the
development of a new generation of melting instrumenta-
tion and the introduction of highly sensitive fluorescent
dye chemistries, allowed the development of Methylation-
Sensitive High-Resolution Melting Analysis (MS-HRMA).
MS-HRMA is based on the different melting profiles of
unmethylated and methylated PCR products, due to
their different sequence composition (CG content) [6].
MS-HRMA is characterized by high sensitivity, reproduci-
bility and accuracy, while it is a closed tube method less
prone to contamination problems [13].
Cystatin M or E/M (encoded by the CST6 gene) is an
endogenous inhibitor of lysosomal cysteine proteases
that functions to protect cells against uncontrolled pro-
teolysis [14]. Cystatin M was first identified and cloned
by Sotiropoulou et al. by differential RNA display as a
transcript that was significantly down-regulated in meta-
static breast cancer cells when compared to primary
breast cancer cells [15]. Later, the same protein was identi-
fied and cloned independently from embryonic lung fibro-
blasts and was named Cystatin E [16]. Cystatin E/M is a
low molecular mass protein sharing 27-32% homology
with other cystatins. Cystatin M has been assigned to
chromosome region 11q13 [17], which is the site of loss of
heterozygosity (LOH) in several cancer types and believed
to harbor tumor suppressor genes. Cystatin M was shown
to directly inhibit the activity of cathepsins B, V, and L
[18,19]. In addition, cystatin M controls the activity of
legumain, which is a known oncogene and an indicator of
poor prognosis in colorectal and breast cancer but was
also found overexpressed in the majority of human solid
tumors [20,21]. Thus, imbalance between proteases andtheir inhibitors cystatins can lead to tumor development,
invasion and metastasis [22]. Analysis of the CST6 gene
shows a single CpG island with many potential methyla-
tion sites in the promoter and the exon 1 of the gene (~64
CpGs in a 507 bp segment) [23] and it was recently shown
that this region is a target for DNA methylation, which
results in loss of cystatin M expression in breast cancer
lines and breast carcinomas [23-25].
We have previously demonstrated that CST6 is hyper-
methylated in breast cancer tissues and that CST6 pro-
moter methylation provides important prognostic
information in patients with operable breast cancer [26].
Moreover we have recently shown that CST6 is epigeneti-
cally silenced in Circulating Tumor Cells (CTC) isolated
from peripheral blood of operable and metastatic breast
cancer patients [27]. Herein, we report a novel closed-
tube MS-HRMA assay for the semi-quantitative determin-
ation of CST6 promoter methylation in clinical samples.
Moreover, performance of the developed CST6 MS-HRMA
assay is compared to the performance of our previously
described methylation specific PCR for CST6.
Methods
Patients and samples
Our study material consisted of a total of 116 clinical sam-
ples: a) one pilot testing group, consisting of 36 samples:
10 paired breast cancer and 10 adjacent histologically nor-
mal non-cancerous tissues, 7 histologically cancer-free
specimens obtained from healthy women during reduc-
tion mammoplasty, and 9 breast fibroadenomas (included
as a separate benign tumor group) and b) one independ-
ent cohort consisting of 80 formalin fixed paraffin-
embedded (FFPE) breast carcinomas, obtained from
patients with operable breast cancer from the Department
of Medical Oncology, University Hospital of Heraklion
Crete. All samples were collected at diagnosis and all
patients gave their informed consent to participate in the
study which has been approved by the Ethical and Scien-
tific Committees of our Institution. Tissue sections of
10 μm containing >80% of tumor cells were used for DNA
extraction and for MS-HRM analysis. Genomic DNA
(gDNA) from paraffin tissues was isolated with the High
Pure PCR Template Preparation kit (Roche, Germany).
DNA concentration was determined in the Nanodrop
ND-1000 spectrophotometer (Nanodrop Technologies,
USA). Before proceeding to the sodium bisulfite conver-
sion and MSP reaction steps, the genomic DNA integrity
of all our clinical samples was assessed by amplifying
BRCA1 exon 20 for mutation analysis by using the same
primers as previously described [28].
Sodium bisulfite conversion
1 μg of extracted DNA was modified with sodium bisul-
fite (SB), in order to convert all unmethylated, but not
Dimitrakopoulos et al. BMC Cancer 2012, 12:486 Page 3 of 11
http://www.biomedcentral.com/1471-2407/12/486methylated-cytosines to uracil. Bisulfite conversion was
carried out using the EZ DNA Methylation Gold Kit
(ZYMO Research Co., Orange, CA), according to the
manufacturer’s instructions. The converted DNA was
stored at −70°C until used. In each sodium bisulfite
conversion reaction, dH2O and breast cancer cell line
MCF-7 were included as a negative and positive control,
respectively.
Controls
Human placental genomic DNA (gDNA; Sigma-Aldrich)
and Universal Methylated Human DNA Standard
(ZYMO Research Co., Orange, CA), were used as fully
unmethylated and fully methylated controls respectively.
Both controls underwent sodium bisulfite conversion,
and a series of synthetic controls containing 0%, 1%,
10%, 50% and 100% methylated DNA were prepared by
spiking the fully methylated DNA control into the
unmethylated. These synthetic methylated DNA controls
were used for the evaluation of the sensitivity of the
assay and the semi-quantitative estimation of CST6
methylation in our clinical samples.
Methylation sensitive high resolution melting (MS-HRM)
In silico primer design
The primer set was designed in silico, using the Primer-
Premier 5 software (Premier Biosoft International, USA),
and synthesized by FORTH (Heraklion, Greece). During
PCR the methylated and unmethylated templates haveFigure 1 The primers of MS-HRM and MSP assays for CST6 promoter
primers are framed, while the inner ones are shown in purple. The region f
Note that this sequence is produced after bisulfite conversion of genomic
unaffected during the conversion process.to be amplified equally so as the percentage of the
methylated products reflects the percentage in the ori-
ginal sample. In low annealing temperatures bias favor
the unmethylated template [29]. Therefore, the anneal-
ing temperature is critical. In order to reverse those PCR
bias, improve the sensitivity of the assay and ensure that
only SB converted DNA is amplified the primer set was
designed according to the guidelines of Wojdacz et al.
[6,30-33]. The sequence for the forward primer is
50-GGTTTAGCGTTAGCGGGAGGTT-30 and for the
reverse primer is 50-AACTCGACACTCACGACTCTAAA
AACTC-30. The PCR amplicon consists of 79 bp, (+9 up to
+87; +1 being the transcriptional start site of CST6 gene)
[34]. The reverse primers are within the same region
that was used for the nested MSP in the same samples as
previously described [26]. The exact position of CGs in the
CST6 gene and the MS-HRMA and MSP primers used in
this study are shown in Figure 1.
PCR
Real-time PCR was performed in the LightCyclerW 480
instrument (Roche Applied Science, Germany) using 96-
well plates (Roche Applied Science, Germany). Extensive
optimization experiments were performed in order to
maximize PCR amplification efficiency, including PCR
program parameters, Mg2+, primer and template con-
centrations. In addition optimization for the annealing
temperature in order to reverse PCR bias as described
above was carried out. 1 μL (~100 ng) of SB convertedmethylation. The MS-HRM primers are shown in red. The outer MSP
rom −162 up to +188 is depicted (+1 is the Transcriptional start site).
DNA. All CpGs are considered to be methylated, and therefore are
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sisted of 1X PCR Buffer (Invitrogen, USA), 0.4 mM for
each dNTP (Invitrogen, USA), 0.05 U/μL PlatinumW Taq
DNA Polymerase (Invitrogen, USA), 0.25 μg/μL BSA
(Sigma, Germany), 1X LCGreen Plus Dye (Idaho Tech-
nology, USA), 0.25 μM primers, and Mg2+ (2.5 mM).
dH2O was used to supplement up to 10μL. The real-
time PCR protocol began with one cycle at 95°C for
5 min followed by 50 cycles of: 95°C for 15 s, 60°C for
10 s and 72°C for 20 s. Immediately after amplification, a
re-annealing cycle consisting of 95°C for 1 min and a
rapid cooling to 70°C for 1 min was introduced in order
to prepare the melting curve acquisition step. Real-time
fluorescence acquisition was set at the elongation step
(72°C). Samples whose amplification begun late or the
relative fluorescence value on the raw melting-curve plot
was low were not further processed. All PCR reactions
were performed in triplicate for each sample.
High resolution melting analysis
All assay optimization studies were performed first in
the HR-1 High Resolution Melter (Idaho Technology,
USA). For this reason, Real-time PCR was performed in
the LightCycler 2.0 instrument using glass capillary
tubes that were transferred after PCR to the HR-1 High
Resolution Melter. Melting data acquisition began at 69°C
and ended in 95°C, using a ramp rate of 0.3°C/s. High
Resolution Melting Analysis was also performed in the
LightCyclerW 480 instrument (Roche Applied Science,
Germany) using 96-well plates (Roche Applied Science,
Germany). Data processing included normalization, and
resulted on the normalized melting curves and the re-
spective negative derivative of fluorescence over the
temperature plots, using the LightCycler 480W gene
scanning software. The settings for data collection were
50 fluorescence acquisition points per degree centigrade
resulting on a ramp rate of 0.01°C/s. Comparison of the
melting curve or the peaks of an unknown sample with
those of the controls gave the semi-quantitative estima-
tion for the methylation level of that sample.
Results
Assay optimization
Fully methylated and fully unmethylated DNA, as well
as synthetic methylated DNA mixtures were used as
controls for the optimization of the assay conditions,
and evaluation of the analytical sensitivity and specificity
of the MS-HRMA assay.
Annealing temperature
Three different annealing temperatures were tested (60°C,
61°C, and 63°C). The normalized melting curves and
the respective derivative plots, as obtained for the syn-
thetic methylated DNA mixtures in all these threetemperatures, were readily distinguishable from each
other at 60°C (Additional file 1 Figure S1).
Analytical sensitivity and specificity
The developed MS-HRMA assay for CST6 methylation
is highly specific for SB treated DNA since under these
experimental conditions only SB treated DNA is ampli-
fied. When genomic DNA isolated from the A13 cell line
that was not SB modified was added, amplification under
the same conditions was not observed (Additional file 2:
Figure S2). We could readily discriminate between SB
treated methylated and SB treated unmethylated con-
trols and no dimers or “non-specific” products were
observed. As can be seen in Figure 2A the unmethylated
and the fully methylated SB treated DNA controls gave
only one peak at their expected Tm values respectively.
To evaluate the analytical sensitivity of the assay, dilu-
tions of fully methylated to fully unmethylated DNA
(1% - 100%) were assessed. The synthetic mixtures
appeared having both peaks as expected. Fluorescence dif-
ference plots were generated and the ability to discrimin-
ate melting transitions of methylated DNA samples from
that of unmethylated DNA samples was assessed. As can
be seen in Figure 2B the presence of 1% of methylated
CST6 sequence can be easily verified in the presence of
99% unmethylated CST6 sequence. When the analysis for
the same control samples was repeated three times in
three different days, melting curves were highly reprodu-
cible (Figure 2A).
Before applying the developed methodology in a high-
throughput format, we compared our results for the
same control samples using both a 96-well plate format
LightCycler 480 (II) instrument (Roche, Germany), and
the HR-1 instrument. Melting transitions presented al-
most identical profiles for both instruments (data not
shown).
Pilot testing group
In the pilot testing group, we analyzed by MS-HRMA
for CST6 methylation 10 paired breast cancer and 10 ad-
jacent non-cancerous (histologically normal) tissues, 7
histologically cancer-free specimens obtained from
healthy women during reduction mammoplasty, and 9
breast fibroadenomas (included as a separate benign
tumor group). The methylation levels ranged from
slightly lower than 1% up to approximately 50%. It is
interesting to note that in the 10 paired breast cancer
and 10 adjacent non-cancerous (histologically normal)
tissues studied, in all cases where the tumor sample was
found negative for methylation, the adjacent non-
cancerous tissue was also negative (Additional file 3:
Table S1). In two cases, where the tumor samples were
methylated at low percentage the adjacent non-
cancerous tissue were also negative. Among the 10
A0%
0%
100% 100%
B
100%
50%
10%
1%
0%
100%
50%
10%
1%
0%
Figure 2 Analytical validation of the MS-HRMA assay for CST6 promoter methylation: A) Specificity and reproducibility of the assay:
0%: human placental genomic DNA, 100% methylated control: universal methylated human DNA standard, run three times at three
different days, B) Sensitivity, Black: 0%, red: 1%, blue: 10%, green: 50%, yellow: 100% methylation.
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mal) tissues tested only one was found to be methylated.
It must be noted that especially in this case, the corre-
sponding tumor sample was heavily methylated (ap-
proximately 50%), and the respective adjacent to the
tumor sample showed only 1% methylation. None of the
7 (0%) histologically cancer-free specimens from reduc-
tion mammoplasty was found to be methylated for CST6
promoter. However, one out of 9 fibroadenomas (11.1%)
showed approximately 10% methylation for CST6 pro-
moter. Moreover, there was a very good concordance be-
tween MS-HRMA and MSP, since in 18/20 (90%) of
these samples MS-HRMA gave the same results as MSP.There were only 2 samples, where MS-HRMA gave
negative results while MSP was positive.
Independent group
We further applied the developed MS-HRMA assay to
evaluate the CST6 methylation status in an independent
cohort consisting of 80 FFPE breast carcinomas samples.
39 out of the 80 tumor samples (48.75%) were found to
be methylated. As can be seen in Figure 3, the melting
patterns of the samples when compared to that of the
spiked control samples with known percentages of CST6
methylation, always run in parallel, allowed for their
classification as non methylated or methylated, while the
Figure 3 Characteristic first derivative MS-HRMA plots for the semi-quantitative estimation of% methylation for CST6 promoter
methylation by MS-HRMA in six tumor FFPE samples: T5:10%, T9: 50%, T13: 1%, T33: 5%, T44: 20% and T52: 20%. Blue: 0%, Red: 50%.
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the latter ones. The clinicopathological characteristics in
respect to the methylation status of CST6 of these
patients are shown in Table 1. As can be seen in Table 1
there was no correlation between CST6 methylation sta-
tus and any clinicopathological parameter studied.
Finally, a graph presenting the methylation percentage
of each sample across various sample categories, is
shown in Figure 4. Mann–Whitney test was performed
to evaluate whether a significant difference in methyla-
tion levels between those groups exist. As can be seen in
this figure, the methylation levels for these 80 tumor
FFPE samples were significantly different than those of
the 10 non-cancerous adjacent to tumor tissues, and the
7 non-cancerous samples, belonging to healthy persons
that underwent mammoplasty surgery, while there was
not a significant difference between these samples and
the 10 tumors of the independent group as well as with
the 9 fibroadenomas tested, since one of them washighly methylated (10%). Nevertheless, the small number
of available fibroadenomas and normal samples do not
allow us to have a clear view in respect to those two
categories.
Comparison between MS-HRMA assay and MSP
In the pilot testing group, when all samples were also
analyzed by our previously reported MSP assay [26]
we found comparable results between the two assays.
More specifically, 29 samples were found negative and
5 samples were found positive by both assays, while
only 2 samples were positive for MSP and negative for
MS-HRMA and no sample was positive by MS-HRMA
and negative by MSP. In the independent group, when all
these samples were also analyzed by our previously
reported MSP assay [26] we also found comparable
results between the two assays. More specifically, 21
samples were found negative and 29 samples were found
positive by both assays, while 20 samples were positive
Table 1 Association of CST6 methylation status with
clinicopathological features for the independent group
(n = 80)
Clinicopathological features CST6 methylation
n + (%) - (%) P value*
Age (years) <55 42 22 (52.4) 20 (47.6) 0.495
≥55 38 17 (44.7) 21 (55.3)
Menopausal status Pre 34 18 (52.9) 16 (47.1) 0.519
Post 46 21 (45.7) 25 (54.3)
Tumor size (cm) 0-2.0 23 11 (47.8) 12 (52.2) 0.682
2.1-5.0 48 22 (45.8) 26 (54.2)
>5.0 8 5 (62.5) 3 (37.5)
Axillary lymph node 0 23 9 (39.1) 14 (60.9) 0.366
1-3 28 14 (50.0) 14 (50.0)
≥4 27 16 (59.3) 11 (40.7)
Tumor grade Ι 22 8 (36.4) 14 (63.6) 0.172
ΙΙ, ΙΙΙ 58 31 (53.4) 27 (46.6)
Estrogen receptor Positive 49 22 (44.9) 27 (55.1) 0.386
Negative 31 17 (54.8) 14 (45.2)
Progesterone receptor Positive 26 10 (38.5) 16 (61.5) 0.201
Negative 54 29 (53.7) 25 (46.3)
*: Chi-square test.
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were positive by MS-HRMA and negative by MSP. In
total, for 84/116 (72.4%) samples the two methods gave
comparable results, (Table 2). More specifically, 50 sam-
ples were found negative and 34 samples were found
positive by both assays, while 22 samples were positiveFigure 4 CTS6 methylation levels as estimated by MS-HRMA in the pi
the Mann–Whitney test.for MSP and negative for MS-HRMA and 10 samples
were positive by MS-HRMA and negative by MSP. For
comparison of these two methods we used the Mac
Nemar test which is a non-parametric method used on
nominal data. According to this test the null hypothesis
of marginal homogeneity states that the two marginal
propabilities for each method are the same. The resulting
P value using a binomial distribution, (P = 0.050) indi-
cated that the two methods are giving comparable
results. Moreover, we have evaluated the agreement be-
tween these two methods by calculating the kappa index
adjusted for a 2-way comparison. This index that has
been developed as a measure of agreement that is cor-
rected for chance and according to the Guidelines for
Strength of Agreement Indicated with Κ Values, the
resulting kappa value of 0.4436 is indicative of a moder-
ate agreement between these two methods [35]. Kappa
index was calculated according to a program that is avail-
able online (http://vassarstats.net/kappa.html) while stat-
istical analysis was performed using the SPSS Windows
version 17.0 (SPSS Inc., Chicago, IL).
Discussion
Cystatin M, originally described as a putative tumor sup-
pressor, whose expression is often diminished or com-
pletely lost in metastatic breast cancers [15] has been
clearly shown to be epigenetically regulated by strong
hypermethylation of the CST6 gene promoter in breast
cancer cell lines [23], in breast cancer and metastatic
lesions in the lymph nodes [34], in malignant gliomas
[36], in cervical [37] and prostate cancer [38]. Becauselot testing group and independent group. P values estimated by
Table 2 Contingency table which tabulates the outcomes of both methods for all samples tested and kappa index
values (n = 116)
Method MSP Total
pos neg
MS-HRM pos 34 10 44
neg 22 50 72
total 56 60 116
Indices of agreement for MS-HRMA and MSP for CST6 methylation
Agreement index Type of agreement Calculated values Standard error CI (95%)
po overall 0.7241
ppos positive 0.6800
pneg negative 0.7575
pe chance 0.5041
Kappa index Chance corrected 0.4436 0.0817 0.2834 – 0.6038
P =0.050, (Mac Nemar test , binomial distribution used.).
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loss of CST6 expression in all tumors alternative modes
of CST6 repression are likely, such as histone deacetyla-
tion and repressive chromatin structure may be involved
[37], since silencing of CST6 has been associated with
repressive trimethyl-H3K27 and dimethyl-H3K9 histone
marks [39].
Recently, CST6 was also identified among 10 hyper-
methylated genes that distinguish between cancerous
and normal tissues according to the extent of methyla-
tion [40]. Moreover, a whole-genome approach using a
human gene promoter tiling microarray platform to
identify genome-wide and gene-specific epigenetic signa-
tures of breast cancer metastasis to lymph nodes led to
functional associations between the methylation status
and expression of genes CDH1, CST6, EGFR, SNAI2 and
ZEB2 associated with epithelial-mesenchymal transition
[41]. In addition, a recent functional epigenetic study of
renal cell carcinoma (RCC) cell lines and primary
tumors by high-density gene expression microarrays
identified CST6 as one of eight genes that showed fre-
quent (>30%) tumor-specific promoter region hyper-
methylation associated with transcriptional silencing
(epigenetically inactivated candidate RCC TSGs).
According to this study, re-expression of BNC1, CST6,
RPRM and SFRP1 suppressed the growth of RCC cell
lines [42]. All these recent studies are in support of the
importance of CST6 promoter methylation in metastasis.
Our group has shown for the first time the prognostic
significance of CST6 promoter methylation in patients
with operable breast cancer [26]. According to our find-
ings, the diagnostic sensitivity and specificity of CST6
methylation as a biomarker for prediction of relapses
and deaths in operable breast cancer seems to be quite
promising [26]. Moreover, we have recently shown that
CST6 promoter was methylated in Circulating Tumor
Cells (CTC) isolated from peripheral blood of breastcancer patients, in both groups of early disease and veri-
fied metastasis [27]. A recent study has also shown that
cystatin M loss may be associated with the losses of ER,
PR, and HER4 in invasive breast cancer [43].
Based on all these studies, we strongly believe that the
reliable and easy detection of CST6 methylation in clin-
ical samples will be of great importance for cancer re-
search. For this reason we decided to develop a closed
tube, highly sensitive, cost-effective, rapid and easy-to-
perform assay for CST6 promoter methylation based on
methylation-sensitive high resolution melting analysis
(MS-HRMA). Resolution of DNA methylation by melt-
ing analysis relies on the fact that the Tm of a PCR
product generated from bisulfite-treated DNA reflects
the methylation status of the original DNA template
[44]. Because unmethylated cytosines will be converted
into uracil during bisulfite treatment and subsequently
amplified as thymine, whereas methylcytosines will re-
main as methylcytosine and be amplified as cytosine, the
methylated sequence will have a higher G:C content,
and hence a higher Tm, than the corresponding
unmethylated sequence. After amplification with primers
that will not differentiate between methylated and
unmethylated molecules, the melting properties of the
PCR products can be examined in the thermal cycler by
slowly elevating the temperature under continuous or
step-wise fluorescence acquisition. The melting curves
or derived melting peaks provide a profile of the methy-
lation status of the entire pool of DNA molecules in the
sample [44].
Many reports have already clearly illustrated the great
potential of melting analysis for sensitive and high-
throughput assessment of DNA methylation in inherited
disorders and cancer [6,11-13,30-33,44]. Compared with
current gel-based assays MS-HRMA has the important
advantage of the closed-tube format, which simplifies the
procedure, decreases the risk of PCR contamination, and
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resolves heterogeneous methylation, detects methylated
and unmethylated alleles in the same reaction, and
requires only standard, inexpensive PCR reagents. In
addition, the design of individual assays is simple [45-47].
The developed assay is highly specific and sensitive
since it can detect the presence of low abundance CST6
methylated DNA sequences (down to 1%). Moreover to
the best of our knowledge, this is the first assay reported
so far that provides additionally a semi-quantitative esti-
mation of CST6 promoter methylation. When compared
to MSP, the developed MS-HRMA gives comparable
but not identical results. The discrepancies between
MS-HRMA and MSP can be explained by the different
principles on which these methods are based. In MSP we
get a positive signal only when the specific CpG island
that the primers are designed for is methylated. However
it is known that different samples can vary in the methy-
lation sites in specific positions in their CpG islands. In
this way if a sample is methylated in positions 3, 6 and 7
and the MSP primers are designed to recognize methyla-
tion in positions 4, 5 and 8, MSP will give a negative re-
sult, while MS-HRMA will give a positive result since it
is affected by the presence of any methylated CpG island
that is located between the primers. In the opposite way,
if the methylation sites that are recognized by the
MSP primers are not included in the region amplified
by MS-HRMA primers a sample found positive by MSP
will be negative by MS-HRMA.
This is the first time that methylation levels for CST6
are reported in clinical samples. Based on our findings,
we can definitely say that these levels vary significantly
among samples. An interesting finding is that a histolo-
gically “non-cancerous” tissue that was adjacent to a
highly methylated (50%) tumor sample was also found to
be methylated, at a lower percentage (1%). CST6 methy-
lation is an early event in breast cancer, since methyla-
tion of the CST6 promoter has already been reported in
7 out of 28 corresponding normal tumor-adjacent breast
tissues samples [25]. This could possibly indicate that
some “normal” cells surrounding the tumor tissue have
already a malignant transformation, not detected by con-
ventional immunohistochemistry. In our study we have
used whole tissue sections containing more than 80% of
tumour cells. However, we can speculate that the per-
centage of contaminating normal cells affect the level of
methylation seen in our samples. For this reason, we be-
lieve that laser capture microdissection could ensure a
higher proportion of lesional cells in clinical samples to
be studied.
Conclusions
The developed methylation-sensitive high resolution melting
assay (MS-HRMA) for the semi-quantitative determinationof CST6 promoter methylation can be a very useful tool to
evaluate reliably and semi-quantitatively CST6 methyla-
tion in a variety of clinical samples. Moreover it is a closed
tube assay, easily applicable in many real time PCR instru-
ments equipped with high resolution melting analysis soft-
ware, cost-effective, rapid and easy-to-perform. It gives
comparable results to MSP in less time, while it offers the
advantage of additionally providing an estimation of the
level of methylation.
Additional files
Additional file 1: Figure S1. Optimization of the annealing
temperature of the MS-HRMA assay for CST6 promoter methylation.
Normalized melting curves and first derivative plots for a) 63ºC: Black: 0%,
red: 1%, blue: 10%, green: 50%, yellow: 100% methylation b) 61ºC: Black:
0%, red: 1%, blue: 10%, yellow: 50%, green: 100% methylation and c)
60ºC: Black: 0%, red: 1%, blue: 10%, green: 50%, yellow: 100% methylation.
Additional file 2: Figure S2. Specificity of MS-HRMA assay for CST6
promoter methylation: PCR products of the SB modified positive controls
and genomic DNA (unconverted). 1) DNA ladder 2) negative control
(H2O), 3) 0% methylated control 4) 1% methylated control 5) 10%
methylated control 6) 50% methylated control 7) 100% methylated
control 8) genomic DNA (unconverted).
Additional file 3: Table S1. CST6 methylation status in 10 paired breast
cancer and 10 adjacent non-cancerous tissues as evaluated by both the
developed MS-HRMA and MSP [26] assays.
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